Eli Lilly said its once-daily weight loss pill was effective for people with obesity and type 2 diabetes in a key trial, clearing the way for the drugmaker to seek regulatory approval across the globe ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

That changed with Ozempic, the brand name for semaglutide, Novo Nordisk’s synthetic version of a hormone known as glucagon-like peptide 1, or GLP-1, which helps the body regulate blood sugar levels.

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...